Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer

Biomarkers

Volumn 18, Issue 2, 2013, Pages 126-135

  Fu, Le ^a   Guo, Wei ^b   Liu, Bingshan ^c   Sun, Linlin ^a   Bi, Zhenghong ^d   Zhu, Li ^e   Wang, Xinyan ^a   Leu, Bin ^a   Xie, Qian ^a   Li, Ke ^a  

^a FUDAN UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

^c 155 Centre Hospital of PLA   (China)

^d HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

^e SHANGHAI CHEST HOSPITAL   (China)

Author keywords

C Met; Lung cancer; S Met; Shedding

Indexed keywords

SCATTER FACTOR RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CANCER SIZE; CHINESE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

AGED; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET; SOLUBILITY; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84873904417     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.751455     Document Type: Article

References (29)

1. Athauda G, Giubellino A, Coleman JA, et al. (2006). c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 12:4154-62.
2. Bean J, Brennan C, Shih JY, et al. (2007). Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932-7.
3. Christensen JG, Burrows J, Salgia R. (2005). c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225:1-26. (Pubitemid 40732764)
4. Cooper CS, Park M, Blair DG, et al. (1984). Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29-33. (Pubitemid 14065275)
5. Engelman JA, Zejnullahu K, Mitsudomi T, et al. (2007). Met amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-43. (Pubitemid 46799492)
6. Galvani AP, Cristiani C, Carpinelli P, et al. (1995). Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form. Biochem Pharmacol 50:959-66.
7. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. (2012). Targeting MET in cancer: rationale and progress. Nature 12:89-103.
8. Glordano S, Di Renzo MF, Narsimban RP, et al. (1989). Biosynthesis of the protein encoded by the c-Met pro-oncogene. Oncogene 4:1383-8. (Pubitemid 19273394)
9. Huh CG, Factor VM, Sanchez A, et al. (2004). Hepatocyte growth factor/ c-Met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 101:4477-82. (Pubitemid 38437436)
10. Klotz M, Schmid E, Steiner-Hahn K, et al. (2012). Preclinical evaluation of biomarkers for response monitoring to the Met inhibitors BAY-853474. Biomarkers (Early online) 4:1-11.
11. Kobayashi N, Aragane N, Nakamura T, et al. (2012). Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma [abstract]. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 31 Mar-4 Apr 2012; Chicago, IL. Philadelphia (PA): AACR Abstract nr 1737.
12. Kosaka T, Yatabe Y, Endoh H, et al. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12:5764-9. (Pubitemid 44629607)
13. Lynch TJ, Bell DW, Sordella R, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to Gefitinib. N Engl J Med 350:2129-39. (Pubitemid 38637993)
14. Marissa NB, Yixuan G, Gregory JR, et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Cancer Lett 12:6494-501.
15. McDermott U, Sharma SV, Dowell L, et al. (2007). Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104:19936-41.
16. Nakamura T, Mizuno S, Matsumoto K, et al. (2000). Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 106:1511-19. (Pubitemid 32038589)
17. Nath D, Williamson N, Jarvis R, Murphy G. (2001). Shedding of c-Met is regulated by crosstalk between a G protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 114:1213-20.
18. Paez JG, Jänne PA, Lee JC, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-500. (Pubitemid 38720929)
19. Park S, Choi YL, Sung CO, et al. (2012). High Met copy number and Met overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 27:197-207.
20. Peruzzi B, Bottaro DP. (2006). Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12:3657-60. (Pubitemid 44000247)
21. Prat M, Crepaldi T, Gandino L, et al. (1991). C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol 11:5954-62. (Pubitemid 21895364)
22. Puri N, Salgia R. (2008). Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinogenesis 7:9-17.
23. Rosell R, Moran T, Queralt C, et al. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-67.
24. Sorbellini M, Mcneil B, Cohen B, et al. (2011). Urinary Met level as a novel biomarker for urothelial carcinoma of the bladder. J Clin Oncol 29:2011(suppl 7; abstr 257) (poster in 2011 Genitourinary Cancer Symposium).
25. Travis WD, Brambilla E, Muller-Hermlink HK. (2004). World Health Organization classification of tumors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press.
26. Wader KF, Fagerli UM, Holt RU, et al. (2011). Soluble c-Met in serum of patients with multiple myeloma correlation with clinical parameters. Eur J Haematol 87:394-9.
27. Wen PY, Schiff D, Cloughesy TF, et al. (2010). A phase 2 study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int 108:679-86.
28. Yu W, Pandita A, Penuel E, et al. (2011a). Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29:2011 (suppl; abstr 7505) (poster and presentation in 2011 ASCO Annual Meeting).
29. Yu W, Pandita A, Penuel E, et al. (2011b). Exploratory biomarker analyses from OAM4558g: a placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced nonsmall cell lung cancer (NSCLC), J Clin Oncol 29: 2011 (suppl; abstr 7529) (poster in 2011 ASCO Annual Meeting).